US Patent 11,040,107: Scope, Claims, Expiration and Patent Landscape for Pegcetacoplan
US Patent 11,040,107 is a method-of-treatment, unit-dose, container, and delivery-device patent directed to pegcetacoplan, Apellis Pharmaceuticals' long-acting C3 complement inhibitor. Its core limitation is narrow but commercially relevant: subcutaneous administration of approximately 1,080 mg of a 40 kDa PEG-linked compstatin dimer on weekly, twice-weekly, thrice-weekly, or every-three-day schedules.
The patent is most important for Paroxysmal Nocturnal Hemoglobinuria (PNH), the approved Empaveli indication. The strongest claims combine four elements: the specified compstatin sequence, two peptide moieties, a 40 kDa PEG clearance-reducing moiety, and the 1,080 mg subcutaneous dosing regimen.
What drug and technology does US Patent 11,040,107 protect?
US 11,040,107 protects clinical use and presentation of pegcetacoplan, also known as APL-2 or Empaveli. Pegcetacoplan is a PEGylated dimeric compstatin analog that inhibits complement component C3.
The claimed molecule has the following architecture:
| Element |
Claimed requirement |
| Active pharmacophore |
Two compstatin analog moieties |
| Peptide structure |
Cyclic peptide containing SEQ ID NO: 28 |
| Terminal modification |
Lysine residue at the N-terminus, C-terminus, or both |
| Spacer |
AEEAc, or 8-amino-3,6-dioxaoctanoic acid |
| Clearance-reducing group |
PEG polymer |
| PEG size |
Average molecular weight of approximately 40 kDa |
| Linkage |
Carbamate linkage at each end of the PEG |
| Administration route |
Subcutaneous |
| Dose |
Approximately 1,080 mg |
| Schedule |
Weekly, twice weekly, thrice weekly, or every three days |
The patent therefore does not broadly cover every compstatin analog, every PEGylated complement inhibitor, or every dose of pegcetacoplan. It targets a defined molecular construct combined with a defined high-dose subcutaneous regimen.
What are the independent claims in US 11,040,107?
The patent has four principal independent claim groups.
Claim 1: Method of treating a complement-mediated disorder
Claim 1 covers administering approximately 1,080 mg of the LACA subcutaneously according to one of four schedules:
- Weekly
- Twice weekly
- Thrice weekly
- Every three days
The method applies to a subject with a complement-mediated disorder. The claimed disorders include hemolytic anemia, PNH, myasthenia gravis, glomerulonephritis, neuromyelitis optica, polyneuropathy, nephropathy, and vasculitis.
The molecule is limited to the specified two-arm, 40 kDa PEG-compstatin structure.
Claim 8: Unit dose
Claim 8 covers a unit dose containing approximately 1,080 mg of the same LACA for subcutaneous administration. This claim is directed to the dose presentation rather than solely to the act of treating a patient.
Dependent claims add:
- Every-three-day administration
- Twice-weekly administration
- Thrice-weekly administration
- A pharmaceutically acceptable carrier
- A syringe or container containing the dose
Claim 15: Treatment using the unit dose
Claim 15 covers administering the claimed unit dose subcutaneously to treat a complement-mediated disorder.
Dependent claims add:
- Syringe-pump administration
- On-body delivery-device administration
- Twice-weekly dosing
- Thrice-weekly dosing
- PNH as the treated disease
Claims 22-24: Structural compound limitations
Claims 22, 23, and 24 expressly tie the method and unit-dose claims to the compound having the claimed approximately 40 kDa PEG structure.
These claims are important because they reduce ambiguity over the identity of the LACA. A competitor cannot avoid the claims merely by describing the active ingredient generically as a compstatin analog if its product uses the claimed PEG-linked dimeric structure.
How broad is the scope of the patent claims?
The patent has moderate overall breadth but strong product-specific coverage.
Broadest practical coverage
The broadest commercial protection arises from the combination of:
- Pegcetacoplan's molecular structure.
- A 1,080 mg subcutaneous dose.
- Treatment of a listed complement-mediated disorder.
- One of the claimed administration schedules.
A competing product that uses the same active ingredient and administers 1,080 mg subcutaneously for PNH would face substantial literal infringement risk if the PEG, spacer, carbamate, peptide sequence, and dosing schedule correspond to the claims.
Material limitations
The claims do not cover:
- Intravenous administration
- Intravitreal administration
- Oral or inhaled administration
- Doses materially different from approximately 1,080 mg
- A monomeric compstatin analog
- A non-PEG clearance-reducing group
- PEG molecules materially outside the approximately 40 kDa limitation
- A different complement inhibitor
- A different peptide sequence lacking the claimed SEQ ID NO: 28 relationship
The word "about" creates numerical flexibility around 1,080 mg and 40 kDa. Its scope would depend on intrinsic evidence in the specification, prosecution history, and expert evidence. A materially lower or higher dose could avoid literal infringement but still create a doctrine-of-equivalents dispute.
What does each claim group protect commercially?
| Claim group |
Primary subject matter |
Commercial importance |
| 1-7 |
Treatment method and dosing schedule |
High for PNH use of Empaveli |
| 8-14 |
Unit dose, carrier, syringe, or container |
Medium to high for finished-dose products |
| 15-21 |
Treatment using the unit dose and delivery devices |
High if on-body or pump administration is used |
| 22-24 |
Express structural limitation to 40 kDa PEG compound |
High for product-identity enforcement |
Claims 2-5 and 18-19 divide the schedules into separate dependent claims. Claims 10 and 11 appear duplicative because both recite twice-weekly administration. The duplication does not materially expand scope, although it may reflect a prosecution or drafting error.
When does US Patent 11,040,107 expire?
US 11,040,107 issued on August 17, 2021. Its ordinary patent term is tied to the earliest effective nonprovisional priority date in the family. Public patent records associate the family with a December 23, 2015 priority date, producing a nominal expiration in December 2035, subject to patent-term adjustment, terminal disclaimers, and any applicable patent-term extension.[1]
The practical exclusivity date must be assessed against the full patent family and FDA Orange Book listing. A later-issued continuation can expire on the same date as an earlier family member if it claims the same priority chain. Patent-term adjustment can extend the nominal date, while a terminal disclaimer can limit it.
| Event |
Date or status |
| Earliest reported family priority |
December 23, 2015 |
| Patent issued |
August 17, 2021 |
| Nominal 20-year expiration |
December 23, 2035 |
| FDA approval of Empaveli |
May 14, 2021 |
| FDA approval of Syfovre |
February 17, 2023 |
| Relevant approved PNH dosing |
1,080 mg subcutaneously twice weekly |
Empaveli received five years of new chemical entity exclusivity from FDA approval, subject to statutory exceptions and the product's classification. That exclusivity period did not replace the patent estate and has already expired. Patent-based exclusivity remains the more important barrier.
What is the Orange Book status of US 11,040,107?
Empaveli is approved under an NDA and its relevant patents are evaluated through the FDA Orange Book framework. The Orange Book identifies patents submitted by the NDA holder for approved drug substance, drug product, or method-of-use protection.[3]
US 11,040,107 is principally a method-of-use and dosage-regimen patent. Its practical Orange Book significance depends on the FDA-listed use code and whether the listed claims correspond to the approved PNH indication.
An Orange Book listing does not establish validity or infringement. It does, however, require an ANDA applicant to address the listed patent through one of the statutory certification routes:
- Paragraph I: no patent information is listed.
- Paragraph II: the patent has expired.
- Paragraph III: the applicant will wait for patent expiration.
- Paragraph IV: the patent is invalid, unenforceable, or will not be infringed.
A Paragraph IV certification can trigger patent litigation if the NDA holder sues within the statutory period. The filing of an ANDA does not itself establish an available launch date.
What Paragraph IV challenges could target the patent?
A generic applicant could challenge US 11,040,107 on several grounds.
Obviousness
The principal challenge would likely combine:
- Earlier compstatin analog disclosures
- PEGylation and half-life extension technology
- Known subcutaneous dosing principles
- Clinical or pharmacokinetic disclosures involving complement inhibition
- The approved or development-stage 1,080 mg regimen
Apellis would argue that the claimed combination produced an unexpected pharmacokinetic or clinical result, particularly the ability to sustain C3 inhibition through subcutaneous dosing at the claimed interval.
Written description and enablement
The claims cover multiple diseases and several administration schedules. A challenger could argue that the specification does not adequately demonstrate possession of every claimed disease, dose interval, delivery format, and clinical setting.
The risk is higher for:
- Weekly dosing
- Every-three-day dosing
- On-body delivery
- Diseases other than PNH
- Broad use of the "about 1,080 mg" range
The risk is lower where the claim maps closely to clinical data and the approved Empaveli regimen.
Indefiniteness
Potential disputes could involve:
- The meaning of "about 1,080 mg"
- The meaning of "about 40 kD"
- The boundaries of the claimed PEG molecular-weight distribution
- Whether a competing PEG linkage is a carbamate
- The structural interpretation of SEQ ID NO: 28 and the AEEAc spacer
Double patenting and terminal disclaimer
The compstatin patent family contains overlapping structural, formulation, dosing, and use claims. An accused infringer could examine whether the claims are patentably distinct from earlier family patents or subject to a terminal disclaimer.
What generic or biosimilar entry risks exist for Empaveli?
Empaveli is not exposed solely to conventional small-molecule generic competition. Pegcetacoplan is a complex PEGylated peptide approved under an NDA, and its regulatory pathway may involve formulation, manufacturing, analytical-characterization, and clinical-comparability issues that differ from a conventional tablet or injectable small molecule.
Generic risk
An ANDA applicant would need to establish pharmaceutical equivalence and bioequivalence to the reference product. The complexity of the PEG-peptide conjugate may create regulatory challenges involving:
- PEG chain distribution
- Conjugation-site consistency
- Dimer purity
- Free peptide and free PEG impurities
- Aggregation
- Potency in C3 inhibition assays
- Subcutaneous absorption
- Immunogenicity and anti-drug antibodies
Biosimilar risk
The principal pathway is not necessarily a traditional 351(k) biosimilar pathway because Empaveli is approved under an NDA rather than a BLA. A competitor may instead pursue an ANDA or a 505(b)(2) application, depending on FDA characterization of the active ingredient and the proposed reliance strategy.
The product's complexity raises technical barriers but does not create absolute protection. A well-capitalized competitor could develop a follow-on PEGylated peptide with a non-infringing structure and pursue regulatory approval without using the exact claimed molecular architecture.
How does the patent compare with competing complement-inhibitor estates?
Pegcetacoplan competes with inhibitors acting at different points in the complement cascade.
| Product |
Target |
Sponsor |
Principal PNH route |
Competitive patent issue |
| Empaveli, pegcetacoplan |
C3 |
Apellis |
Subcutaneous |
Product, dosing, formulation, and method claims |
| Soliris, eculizumab |
C5 |
Alexion/AstraZeneca |
Intravenous |
Mature composition and use estate; biosimilar and follow-on risk |
| Ultomiris, ravulizumab |
C5 |
Alexion/AstraZeneca |
Intravenous |
Extended-interval dosing and formulation protection |
| Fabhalta, iptacopan |
Factor B |
Novartis |
Oral |
Small-molecule composition and use claims |
| Voydeya, danicopan |
Factor D |
Alexion/AstraZeneca |
Oral adjunct |
Composition and combination-use claims |
| PiaSky, crovalimab |
C5 |
Roche |
Subcutaneous or intravenous |
Antibody composition, dosing, and device claims |
Pegcetacoplan's differentiated commercial position is subcutaneous C3 inhibition. That feature also concentrates infringement risk around the exact 1,080 mg regimen claimed in US 11,040,107.
What manufacturing and intellectual-property barriers affect entry?
The manufacturing claims of US 11,040,107 are limited. The patent is primarily directed to treatment methods, unit doses, containers, and administration systems. It does not, based on the supplied claims, broadly claim the entire manufacturing process for pegcetacoplan.
Manufacturing barriers nevertheless remain significant because a follow-on manufacturer would need to reproduce:
- The cyclic peptide sequence
- Correct AEEAc spacer placement
- Site-specific or controlled PEG conjugation
- Approximately 40 kDa PEG characteristics
- Carbamate linkages
- Dimer stoichiometry
- Low levels of unconjugated and mis-conjugated species
- Comparable potency and stability
A competitor could reduce infringement risk by changing one or more of these parameters, but each change may create a regulatory comparability problem. The strongest freedom-to-operate strategy would likely involve a structurally distinct complement inhibitor rather than a near-copy of pegcetacoplan.
What litigation and licensing issues affect the patent?
The available claim set indicates an Apellis-centered patent estate around pegcetacoplan and related compstatin technology. The relevant commercial risks include:
- Orange Book listing and Paragraph IV litigation
- Patent-family double-patenting analysis
- Challenges to dosage-regimen obviousness
- Disputes over PEG molecular weight and carbamate linkage
- Use-code disputes involving PNH
- Follow-on product litigation under the Hatch-Waxman framework
- Potential disputes over formulation or delivery-device patents
Apellis' development of pegcetacoplan is associated with licensed or acquired compstatin technology originating from academic research. The commercial protection is distributed across composition, conjugation, formulation, dosing, and therapeutic-use patents rather than depending on US 11,040,107 alone.[5]
No license grants a third party freedom to practice the claims merely because the third party uses a different regulatory pathway. Patent rights and FDA approval are separate issues.
How strong is the patent estate for pegcetacoplan?
US 11,040,107 is strongest against a direct copy of Empaveli's approved PNH regimen. Its risk profile can be summarized as follows:
| Issue |
Assessment |
| Exact Empaveli structure |
Strong infringement leverage |
| 1,080 mg subcutaneous PNH dosing |
Strong commercial relevance |
| Weekly and every-three-day schedules |
More vulnerable than approved twice-weekly use if clinical support is limited |
| Unit-dose and container claims |
Useful but narrower than treatment claims |
| On-body delivery claims |
Potentially valuable for lifecycle management |
| Broad non-PNH indications |
Greater enablement and written-description exposure |
| Manufacturing protection |
Limited under the supplied claims |
| Follow-on product risk |
Moderate; depends on structural similarity |
| Conventional generic risk |
Constrained by molecular complexity |
| Biosimilar risk |
Secondary to ANDA or 505(b)(2) strategies |
What generic launch scenarios exist for Empaveli?
Scenario 1: No challenge before patent expiry
A competitor waits for the relevant patent barriers to expire. This is the lowest litigation-risk path but delays entry until the mid-2030s unless other patents expire earlier.
Scenario 2: Paragraph IV challenge
An ANDA applicant certifies that US 11,040,107 is invalid, unenforceable, or not infringed. Apellis may sue, creating a 30-month stay of FDA approval under applicable Hatch-Waxman provisions, subject to statutory exceptions.
Scenario 3: Non-infringing molecular redesign
A competitor develops a PEGylated compstatin analog with a different sequence, linker, polymer, linkage, or molecular weight. This avoids direct literal infringement but creates clinical, analytical, and regulatory-development risk.
Scenario 4: Alternative complement inhibitor
A competitor launches an oral factor B, factor D, or C5 inhibitor. This avoids the patent claims entirely but competes for the same PNH population through a different mechanism and dosing model.
Key Takeaways
- US 11,040,107 protects pegcetacoplan treatment, unit doses, containers, and delivery methods.
- The central claim combination is approximately 1,080 mg subcutaneous dosing of a two-arm, 40 kDa PEG-compstatin analog.
- PNH is the most commercially important claimed indication.
- The patent has a nominal expiration in December 2035 based on the reported priority chain, subject to patent-term adjustment and related statutory factors.
- The patent is strongest against a direct Empaveli copy using the same molecule and twice-weekly 1,080 mg regimen.
- Weekly, every-three-day, non-PNH, and device-related embodiments present greater validity and scope questions.
- Follow-on competition is more likely to involve a complex generic, 505(b)(2) product, or structurally distinct complement inhibitor than a conventional biosimilar.
- The patent does not, based on the supplied claims, broadly protect pegcetacoplan manufacturing methods.
- Claims 10 and 11 are duplicative on their face and do not materially expand the claim scope.
- The full commercial risk depends on the broader Apellis patent family, Orange Book listings, patent-term adjustments, and any Paragraph IV litigation.
FAQs About US Patent 11,040,107 and Pegcetacoplan
Does US 11,040,107 cover Empaveli itself?
It covers methods, unit doses, containers, and administration systems using the claimed 40 kDa PEG-linked compstatin dimer. It is not a simple composition-of-matter claim covering every form of pegcetacoplan in every context.
Does the patent cover 1,080 mg intravenous pegcetacoplan?
No. The supplied claims require subcutaneous administration. Intravenous administration does not satisfy that express route limitation.
Can a competitor avoid the patent by using a 20 kDa PEG polymer?
A 20 kDa PEG construct would have a substantial non-infringement argument against the approximately 40 kDa limitation, although equivalence and other family patents would require separate analysis.
Does the patent cover treatment of geographic atrophy?
The supplied claims do not expressly recite geographic atrophy. Syfovre is approved for geographic atrophy secondary to age-related macular degeneration, but these claims are directed to subcutaneous treatment of complement-mediated disorders, not intravitreal geographic-atrophy treatment.
Is pegcetacoplan subject to biosimilar competition?
Pegcetacoplan's principal follow-on risk may arise through an ANDA or 505(b)(2) route rather than a conventional 351(k) biosimilar application because Empaveli is an NDA-approved product. The applicable pathway depends on FDA product classification and the follow-on sponsor's proposed reliance strategy.
References
- United States Patent and Trademark Office. (2021). US Patent No. 11,040,107, methods of treating complement-mediated disorders using long-acting compstatin analogs.
- U.S. Food and Drug Administration. (2021). Empaveli (pegcetacoplan) prescribing information.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (2021, May 14). FDA approves Empaveli to treat adults with paroxysmal nocturnal hemoglobinuria.
- Apellis Pharmaceuticals, Inc. (2024). Form 10-K annual report.
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
